Big week for Alzheimer’s da­ta; As­traZeneca buys cell ther­a­py start­up; Dig­i­tal ther­a­peu­tics hits a pay­er wall; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

You may start to no­tice more sto­ries ex­clu­sive­ly avail­able to Pre­mi­um sub­scribers. This week alone, paid sub­scribers can read our in-depth re­port­ing on Alzheimer’s da­ta, dig­i­tal ther­a­peu­tics and Al­lo­gene’s cell ther­a­py for sol­id tu­mors, as well as scoops on Twit­ter ads and Catal­ent. With your sup­port, we can keep grow­ing our team and spend more time on qual­i­ty work. We have both in­di­vid­ual and com­pa­ny plans avail­able — check them out to un­lock the full End­points ex­pe­ri­ence.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.